Treatment and prevention of mania in bipolar&nbsp;I disorder: focus on aripiprazole | Zendy

David J. Muzina | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

Author(s) -

David J. Muzina

Publication year - 2009

Publication title -

neuropsychiatric disease and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.819

H-Index - 67

eISSN - 1178-2021

pISSN - 1176-6328

DOI - 10.2147/ndt.s3763

Subject(s) - aripiprazole , medicine , mania , bipolar disorder , psychiatry , treatment of bipolar disorder , pharmacology , psychotherapist , lithium (medication) , schizophrenia (object oriented programming) , psychology

Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole's place in therapy for bipolar mania will be covered.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research